Deniz Kirik - Publications

Affiliations: 
Brain Repair and Imaging in Neural Systems Lund University, Lund, Skåne län, Sweden 
Area:
Parkinson's Disease, Disease models

152 high-probability publications. We are testing a new system for linking publications to authors. You can help! If you notice any inaccuracies, please sign in and mark papers as correct or incorrect matches. If you identify any major omissions or other inaccuracies in the publication list, please let us know.

Year Citation  Score
2018 Lillethorup TP, Glud AN, Alstrup AKO, Noer O, Nielsen EHT, Schacht AC, Landeck N, Kirik D, Orlowski D, Sørensen JCH, Doudet DJ, Landau AM. Longitudinal monoaminergic PET imaging of chronic proteasome inhibition in minipigs. Scientific Reports. 8: 15715. PMID 30356172 DOI: 10.1038/s41598-018-34084-5  0.44
2018 Baldo B, Sajjad MU, Cheong RY, Bigarreau J, Vijayvargia R, McLean C, Perrier AL, Seong IS, Halliday G, Petersén Å, Kirik D. Quantification of Total and Mutant Huntingtin Protein Levels in Biospecimens Using a Novel alphaLISA Assay. Eneuro. 5. PMID 30310861 DOI: 10.1523/ENEURO.0234-18.2018  0.6
2018 Baldo B, Gabery S, Soylu-Kucharz R, Cheong RY, Henningsen JB, Englund E, McLean C, Kirik D, Halliday G, Petersén Å. SIRT1 is increased in affected brain regions and hypothalamic metabolic pathways are altered in Huntington disease. Neuropathology and Applied Neurobiology. PMID 30019499 DOI: 10.1111/nan.12514  0.6
2018 Pinholt Lillethorup T, Glud AN, Landeck N, Alstrup AKO, Jakobsen S, Vang K, Doudet DJ, Brooks DJ, Kirik D, Hinz R, Sørensen JC, Landau AM. In vivo Quantification of Glial Activation in Minipigs Overexpressing human α-synuclein. Synapse (New York, N.Y.). PMID 30009467 DOI: 10.1002/syn.22060  0.44
2017 Hansen MG, Ledri LN, Kirik D, Kokaia M, Ledri M. Preserved Function of Afferent Parvalbumin-Positive Perisomatic Inhibitory Synapses of Dentate Granule Cells in Rapidly Kindled Mice. Frontiers in Cellular Neuroscience. 11: 433. PMID 29375319 DOI: 10.3389/fncel.2017.00433  0.68
2017 Mandel RJ, Marmion DJ, Kirik D, Chu Y, Heindel C, McCown T, Gray SJ, Kordower JH. Novel oligodendroglial alpha synuclein viral vector models of multiple system atrophy: studies in rodents and nonhuman primates. Acta Neuropathologica Communications. 5: 47. PMID 28619074 DOI: 10.1186/s40478-017-0451-7  0.64
2016 Landeck N, Buck K, Kirik D. Toxic effects of human and rodent variants of alpha-synuclein in vivo. The European Journal of Neuroscience. PMID 27893183 DOI: 10.1111/ejn.13493  0.44
2016 Kirik D, Cederfjäll E, Halliday G, Petersén Å. Gene therapy for Parkinson's disease: Disease modification by GDNF family of ligands. Neurobiology of Disease. PMID 27616425 DOI: 10.1016/j.nbd.2016.09.008  0.68
2016 Naughton C, O'Toole D, Kirik D, Dowd E. Interaction between subclinical doses of the Parkinson's disease associated gene, α-synuclein, and the pesticide, rotenone, precipitates motor dysfunction and nigrostriatal neurodegeneration in rats. Behavioural Brain Research. PMID 27585560 DOI: 10.1016/j.bbr.2016.08.056  1
2016 Landeck N, Hall H, Ardah MT, Majbour NK, El-Agnaf OM, Halliday G, Kirik D. A novel multiplex assay for simultaneous quantification of total and S129 phosphorylated human alpha-synuclein. Molecular Neurodegeneration. 11: 61. PMID 27549140 DOI: 10.1186/s13024-016-0125-0  0.64
2016 Volpicelli-Daley LA, Kirik D, Stoyka LE, Standaert DG, Harms AS. How can rAAV-α-synuclein and the fibril α-synuclein models advance our understanding of Parkinson disease? Journal of Neurochemistry. PMID 27018978 DOI: 10.1111/jnc.13627  1
2016 Cuellar-Baena S, Landeck N, Sonnay S, Buck K, Mlynarik V, Zandt RI, Kirik D. Assessment of brain metabolite correlates of AAV-mediated overexpression of human alpha-synuclein in cortical neurons by in vivo(1) H-MR spectroscopy at 9.4 T. Journal of Neurochemistry. PMID 26811128 DOI: 10.1111/jnc.13547  0.6
2015 Kuzdas-Wood D, Fellner L, Premstaller M, Borm C, Bloem B, Kirik D, Wenning GK, Stefanova N. Overexpression of α-synuclein in oligodendrocytes does not increase susceptibility to focal striatal excitotoxicity. Bmc Neuroscience. 16: 86. PMID 26627686 DOI: 10.1186/s12868-015-0227-6  1
2015 Soylu-Kucharz R, Adlesic N, Baldo B, Kirik D, Petersén Å. Hypothalamic overexpression of mutant huntingtin causes dysregulation of brown adipose tissue. Scientific Reports. 5: 14598. PMID 26419281 DOI: 10.1038/srep14598  1
2015 Buck K, Landeck N, Ulusoy A, Majbour NK, El-Agnaf OM, Kirik D. Ser129 phosphorylation of endogenous α-synuclein induced by overexpression of polo-like kinases 2 and 3 in nigral dopamine neurons is not detrimental to their survival and function. Neurobiology of Disease. 78: 100-14. PMID 25818009 DOI: 10.1016/j.nbd.2015.03.008  1
2015 Gabery S, Halliday G, Kirik D, Englund E, Petersén Å. Selective loss of oxytocin and vasopressin in the hypothalamus in early Huntington disease: a case study. Neuropathology and Applied Neurobiology. PMID 25765897 DOI: 10.1111/nan.12236  1
2015 Gabery S, Georgiou-Karistianis N, Lundh SH, Cheong RY, Churchyard A, Chua P, Stout JC, Egan GF, Kirik D, Petersén Ã…. Volumetric analysis of the hypothalamus in Huntington Disease using 3T MRI: the IMAGE-HD Study. Plos One. 10: e0117593. PMID 25659157 DOI: 10.1371/journal.pone.0117593  1
2015 Cederfjäll E, Broom L, Kirik D. Controlled Striatal DOPA Production From a Gene Delivery System in a Rodent Model of Parkinson's Disease. Molecular Therapy : the Journal of the American Society of Gene Therapy. 23: 896-906. PMID 25592335 DOI: 10.1038/mt.2015.8  1
2014 Hall H, Reyes S, Landeck N, Bye C, Leanza G, Double K, Thompson L, Halliday G, Kirik D. Hippocampal Lewy pathology and cholinergic dysfunction are associated with dementia in Parkinson's disease. Brain : a Journal of Neurology. 137: 2493-508. PMID 25062696 DOI: 10.1093/brain/awu193  1
2014 Petersén A, Kirik D. Twisting mice move the dystonia field forward. The Journal of Clinical Investigation. 124: 2848-50. PMID 24937421 DOI: 10.1172/JCI76624  1
2014 Sahin G, Thompson LH, Lavisse S, Ozgur M, Rbah-Vidal L, Dollé F, Hantraye P, Kirik D. Differential dopamine receptor occupancy underlies L-DOPA-induced dyskinesia in a rat model of Parkinson's disease. Plos One. 9: e90759. PMID 24614598 DOI: 10.1371/journal.pone.0090759  1
2014 Ledri M, Madsen MG, Nikitidou L, Kirik D, Kokaia M. Global optogenetic activation of inhibitory interneurons during epileptiform activity. The Journal of Neuroscience : the Official Journal of the Society For Neuroscience. 34: 3364-77. PMID 24573293 DOI: 10.1523/JNEUROSCI.2734-13.2014  1
2014 Berglind F, Ledri M, Sørensen AT, Nikitidou L, Melis M, Bielefeld P, Kirik D, Deisseroth K, Andersson M, Kokaia M. Optogenetic inhibition of chemically induced hypersynchronized bursting in mice. Neurobiology of Disease. 65: 133-41. PMID 24491965 DOI: 10.1016/j.nbd.2014.01.015  1
2014 Moloney TC, Hyland R, O'Toole D, Paucard A, Kirik D, O'Doherty A, Gorman AM, Dowd E. Heat shock protein 70 reduces α-synuclein-induced predegenerative neuronal dystrophy in the α-synuclein viral gene transfer rat model of Parkinson's disease. Cns Neuroscience & Therapeutics. 20: 50-8. PMID 24279716 DOI: 10.1111/cns.12200  1
2013 Xilouri M, Brekk OR, Kirik D, Stefanis L. LAMP2A as a therapeutic target in Parkinson disease. Autophagy. 9: 2166-8. PMID 24145820 DOI: 10.4161/auto.26451  1
2013 Cederfjäll E, Nilsson N, Sahin G, Chu Y, Nikitidou E, Björklund T, Kordower JH, Kirik D. Continuous DOPA synthesis from a single AAV: dosing and efficacy in models of Parkinson's disease. Scientific Reports. 3: 2157. PMID 23831692 DOI: 10.1038/srep02157  1
2013 Xilouri M, Brekk OR, Landeck N, Pitychoutis PM, Papasilekas T, Papadopoulou-Daifoti Z, Kirik D, Stefanis L. Boosting chaperone-mediated autophagy in vivo mitigates α-synuclein-induced neurodegeneration. Brain : a Journal of Neurology. 136: 2130-46. PMID 23757764 DOI: 10.1093/brain/awt131  1
2013 Hall H, Jewett M, Landeck N, Nilsson N, Schagerlöf U, Leanza G, Kirik D. Characterization of cognitive deficits in rats overexpressing human alpha-synuclein in the ventral tegmental area and medial septum using recombinant adeno-associated viral vectors. Plos One. 8: e64844. PMID 23705016 DOI: 10.1371/journal.pone.0064844  1
2013 Hult Lundh S, Nilsson N, Soylu R, Kirik D, Petersén Ã…. Hypothalamic expression of mutant huntingtin contributes to the development of depressive-like behavior in the BAC transgenic mouse model of Huntington's disease. Human Molecular Genetics. 22: 3485-97. PMID 23697793 DOI: 10.1093/hmg/ddt203  1
2013 Reyes S, Cottam V, Kirik D, Double KL, Halliday GM. Variability in neuronal expression of dopamine receptors and transporters in the substantia nigra. Movement Disorders : Official Journal of the Movement Disorder Society. 28: 1351-9. PMID 23674405 DOI: 10.1002/mds.25493  1
2013 Febbraro F, Sahin G, Farran A, Soares S, Jensen PH, Kirik D, Romero-Ramos M. Ser129D mutant alpha-synuclein induces earlier motor dysfunction while S129A results in distinctive pathology in a rat model of Parkinson's disease. Neurobiology of Disease. 56: 47-58. PMID 23567651 DOI: 10.1016/j.nbd.2013.03.014  1
2013 Mulcahy P, O'Doherty A, Paucard A, O'Brien T, Kirik D, Dowd E. The behavioural and neuropathological impact of intranigral AAV-α-synuclein is exacerbated by systemic infusion of the Parkinson's disease-associated pesticide, rotenone, in rats. Behavioural Brain Research. 243: 6-15. PMID 23295396 DOI: 10.1016/j.bbr.2012.12.051  1
2013 Hall H, Cuellar-Baena S, Denisov V, Kirik D. Development of NMR spectroscopic methods for dynamic detection of acetylcholine synthesis by choline acetyltransferase in hippocampal tissue. Journal of Neurochemistry. 124: 336-46. PMID 23004566 DOI: 10.1111/jnc.12025  1
2013 Oksman M, Wisman LA, Jiang H, Miettinen P, Kirik D, Tanila H. Transduced wild-type but not P301S mutated human tau shows hyperphosphorylation in transgenic mice overexpressing A30P mutated human alpha-synuclein. Neuro-Degenerative Diseases. 12: 91-102. PMID 22948283 DOI: 10.1159/000341596  1
2013 Reyes S, Fu Y, Double KL, Cottam V, Thompson LH, Kirik D, Paxinos G, Watson C, Cooper HM, Halliday GM. Trophic factors differentiate dopamine neurons vulnerable to Parkinson's disease. Neurobiology of Aging. 34: 873-86. PMID 22926168 DOI: 10.1016/j.neurobiolaging.2012.07.019  1
2013 Bezard E, Yue Z, Kirik D, Spillantini MG. Animal models of Parkinson's disease: limits and relevance to neuroprotection studies. Movement Disorders : Official Journal of the Movement Disorder Society. 28: 61-70. PMID 22753348 DOI: 10.1002/mds.25108  1
2013 Febbraro F, Sahin G, Farran A, Soares S, Jensen PH, Kirik D, Romero-Ramos M. Corrigendum to "Ser129D mutant alpha-synuclein induces earlier motor dysfunction while S129A results in distinctive pathology in a rat model of Parkinson's disease" [Neurobiol. Dis. 56 (2013) 48-58] Neurobiology of Disease. 58: 191. DOI: 10.1016/j.nbd.2013.06.003  1
2013 Xilouri M, Brekk O, Landeck N, Papasilekas T, Pitichoutis T, Vekrellis K, Daifoti Z, Kirik D, Stefanis L. Induction of Chaperone-Mediated Autophagy as a Means to Attenuate Alpha-Synuclein-Mediated Neurotoxicity Catecholamine Research in the 21st Century: Abstracts and Graphical Abstracts, 10th International Catecholamine Symposium, 2012. 129-130. DOI: 10.1016/B978-0-12-800044-1.00113-6  1
2012 Kordower JH, Kirik D. Introduction: gene therapy has gone from a pipe dream to clinical reality. Neurobiology of Disease. 48: 151-2. PMID 22841531 DOI: 10.1016/j.nbd.2012.07.014  1
2012 Gabery S, Sajjad MU, Hult S, Soylu R, Kirik D, Petersén Ã…. Characterization of a rat model of Huntington's disease based on targeted expression of mutant huntingtin in the forebrain using adeno-associated viral vectors. The European Journal of Neuroscience. 36: 2789-800. PMID 22731249 DOI: 10.1111/j.1460-9568.2012.08193.x  1
2012 Ulusoy A, Björklund T, Buck K, Kirik D. Dysregulated dopamine storage increases the vulnerability to α-synuclein in nigral neurons. Neurobiology of Disease. 47: 367-77. PMID 22659302 DOI: 10.1016/j.nbd.2012.05.012  1
2012 Lastres-Becker I, Ulusoy A, Innamorato NG, Sahin G, Rábano A, Kirik D, Cuadrado A. α-Synuclein expression and Nrf2 deficiency cooperate to aggravate protein aggregation, neuronal death and inflammation in early-stage Parkinson's disease. Human Molecular Genetics. 21: 3173-92. PMID 22513881 DOI: 10.1093/hmg/dds143  1
2012 Ledri M, Nikitidou L, Erdelyi F, Szabo G, Kirik D, Deisseroth K, Kokaia M. Altered profile of basket cell afferent synapses in hyper-excitable dentate gyrus revealed by optogenetic and two-pathway stimulations. The European Journal of Neuroscience. 36: 1971-83. PMID 22512307 DOI: 10.1111/j.1460-9568.2012.08080.x  1
2012 Barkholt P, Sanchez-Guajardo V, Kirik D, Romero-Ramos M. Long-term polarization of microglia upon α-synuclein overexpression in nonhuman primates. Neuroscience. 208: 85-96. PMID 22342967 DOI: 10.1016/j.neuroscience.2012.02.004  1
2012 Cederfjäll E, Sahin G, Kirik D, Björklund T. Design of a single AAV vector for coexpression of TH and GCH1 to establish continuous DOPA synthesis in a rat model of Parkinson's disease. Molecular Therapy : the Journal of the American Society of Gene Therapy. 20: 1315-26. PMID 22294150 DOI: 10.1038/mt.2012.1  1
2012 Reyes S, Fu Y, Double K, Thompson L, Kirik D, Paxinos G, Halliday GM. GIRK2 expression in dopamine neurons of the substantia nigra and ventral tegmental area. The Journal of Comparative Neurology. 520: 2591-607. PMID 22252428 DOI: 10.1002/cne.23051  1
2012 Mulcahy P, O'Doherty A, Paucard A, O'Brien T, Kirik D, Dowd E. Development and characterisation of a novel rat model of Parkinson's disease induced by sequential intranigral administration of AAV-α-synuclein and the pesticide, rotenone. Neuroscience. 203: 170-9. PMID 22198020 DOI: 10.1016/j.neuroscience.2011.12.011  1
2012 Hall H, Cuellar-Baena S, Dahlberg C, In't Zandt R, Denisov V, Kirik D. Magnetic resonance spectroscopic methods for the assessment of metabolic functions in the diseased brain. Current Topics in Behavioral Neurosciences. 11: 169-98. PMID 22076698 DOI: 10.1007/7854_2011_166  1
2012 Xilouri M, Kyratzi E, Pitychoutis PM, Papadopoulou-Daifoti Z, Perier C, Vila M, Maniati M, Ulusoy A, Kirik D, Park DS, Wada K, Stefanis L. Selective neuroprotective effects of the S18Y polymorphic variant of UCH-L1 in the dopaminergic system. Human Molecular Genetics. 21: 874-89. PMID 22076440 DOI: 10.1093/hmg/ddr521  1
2012 Cederfjäll E, Sahin G, Kirik D. Key factors determining the efficacy of gene therapy for continuous DOPA delivery in the Parkinsonian brain. Neurobiology of Disease. 48: 222-7. PMID 22048069 DOI: 10.1016/j.nbd.2011.10.017  1
2011 Ulusoy A, Kirik D. Development of advanced therapies based on viral vector-mediated overexpression of therapeutic molecules and knockdown of disease-related genes for Parkinson's disease. Therapeutic Delivery. 2: 37-50. PMID 22833924 DOI: 10.4155/tde.10.95  1
2011 Decressac M, Ulusoy A, Mattsson B, Georgievska B, Romero-Ramos M, Kirik D, Björklund A. GDNF fails to exert neuroprotection in a rat α-synuclein model of Parkinson's disease. Brain : a Journal of Neurology. 134: 2302-11. PMID 21712347 DOI: 10.1093/brain/awr149  1
2011 Hult S, Soylu R, Björklund T, Belgardt BF, Mauer J, Brüning JC, Kirik D, Petersén Ã…. Mutant huntingtin causes metabolic imbalance by disruption of hypothalamic neurocircuits. Cell Metabolism. 13: 428-39. PMID 21459327 DOI: 10.1016/j.cmet.2011.02.013  1
2011 Tran TA, Kirik D. Imaging of brain prion protein amyloid in patients with Gertstmann-Sträussler-Scheinker disease | slikanje prionskega proteina možganov beta-amiloida pri bolnikih z Gerstmann-Sträussler-Scheinkerjevim sindromom Zdravniski Vestnik. 80: 969-970.  1
2011 Sahin G, Kirik D. Efficacy of L-DOPA therapy in Parkinson's disease Amino Acids in Human Nutrition and Health. 454-463.  1
2010 Dodiya HB, Bjorklund T, Stansell Iii J, Mandel RJ, Kirik D, Kordower JH. Differential Transduction Following Basal Ganglia Administration of Distinct Pseudotyped AAV Capsid Serotypes in Nonhuman Primates. Molecular Therapy : the Journal of the American Society of Gene Therapy. 18: 579-587. PMID 28182881 DOI: 10.1038/mt.2009.216  0.64
2010 Björklund T, Cederfjäll EA, Kirik D. Gene therapy for dopamine replacement. Progress in Brain Research. 184: 221-35. PMID 20887878 DOI: 10.1016/S0079-6123(10)84012-9  1
2010 Ulusoy A, Decressac M, Kirik D, Björklund A. Viral vector-mediated overexpression of α-synuclein as a progressive model of Parkinson's disease. Progress in Brain Research. 184: 89-111. PMID 20887871 DOI: 10.1016/S0079-6123(10)84005-1  1
2010 Iwamoto M, Björklund T, Lundberg C, Kirik D, Wandless TJ. A general chemical method to regulate protein stability in the mammalian central nervous system. Chemistry & Biology. 17: 981-8. PMID 20851347 DOI: 10.1016/j.chembiol.2010.07.009  1
2010 Gabery S, Murphy K, Schultz K, Loy CT, McCusker E, Kirik D, Halliday G, Petersén A. Changes in key hypothalamic neuropeptide populations in Huntington disease revealed by neuropathological analyses. Acta Neuropathologica. 120: 777-88. PMID 20821223 DOI: 10.1007/s00401-010-0742-6  1
2010 Ulusoy A, Febbraro F, Jensen PH, Kirik D, Romero-Ramos M. Co-expression of C-terminal truncated alpha-synuclein enhances full-length alpha-synuclein-induced pathology. The European Journal of Neuroscience. 32: 409-22. PMID 20704592 DOI: 10.1111/j.1460-9568.2010.07284.x  1
2010 Soneson C, Fontes M, Zhou Y, Denisov V, Paulsen JS, Kirik D, Petersén A. Early changes in the hypothalamic region in prodromal Huntington disease revealed by MRI analysis. Neurobiology of Disease. 40: 531-43. PMID 20682340 DOI: 10.1016/j.nbd.2010.07.013  1
2010 Ulusoy A, Sahin G, Kirik D. Presynaptic dopaminergic compartment determines the susceptibility to L-DOPA-induced dyskinesia in rats. Proceedings of the National Academy of Sciences of the United States of America. 107: 13159-64. PMID 20615977 DOI: 10.1073/pnas.1003432107  1
2010 Cudalbu C, Comment A, Kurdzesau F, van Heeswijk RB, Uffmann K, Jannin S, Denisov V, Kirik D, Gruetter R. Feasibility of in vivo 15N MRS detection of hyperpolarized 15N labeled choline in rats. Physical Chemistry Chemical Physics : Pccp. 12: 5818-23. PMID 20461252 DOI: 10.1039/c002309b  1
2010 Carta M, Carlsson T, Muñoz A, Kirik D, Björklund A. Role of serotonin neurons in the induction of levodopa- and graft-induced dyskinesias in Parkinson's disease. Movement Disorders : Official Journal of the Movement Disorder Society. 25: S174-9. PMID 20187238 DOI: 10.1002/mds.22792  1
2010 Björklund T, Carlsson T, Cederfjäll EA, Carta M, Kirik D. Optimized adeno-associated viral vector-mediated striatal DOPA delivery restores sensorimotor function and prevents dyskinesias in a model of advanced Parkinson's disease. Brain : a Journal of Neurology. 133: 496-511. PMID 20129936 DOI: 10.1093/brain/awp314  1
2010 Grealish S, Jönsson ME, Li M, Kirik D, Björklund A, Thompson LH. The A9 dopamine neuron component in grafts of ventral mesencephalon is an important determinant for recovery of motor function in a rat model of Parkinson's disease. Brain : a Journal of Neurology. 133: 482-95. PMID 20123725 DOI: 10.1093/brain/awp328  1
2010 Sanchez-Guajardo V, Febbraro F, Kirik D, Romero-Ramos M. Microglia acquire distinct activation profiles depending on the degree of alpha-synuclein neuropathology in a rAAV based model of Parkinson's disease. Plos One. 5: e8784. PMID 20098715 DOI: 10.1371/journal.pone.0008784  1
2010 Kornum BR, Stott SR, Mattsson B, Wisman L, Ettrup A, Hermening S, Knudsen GM, Kirik D. Adeno-associated viral vector serotypes 1 and 5 targeted to the neonatal rat and pig striatum induce widespread transgene expression in the forebrain. Experimental Neurology. 222: 70-85. PMID 20025873 DOI: 10.1016/j.expneurol.2009.12.009  1
2010 Dodiya HB, Bjorklund T, Stansell J, Mandel RJ, Kirik D, Kordower JH. Differential transduction following basal ganglia administration of distinct pseudotyped AAV capsid serotypes in nonhuman primates. Molecular Therapy : the Journal of the American Society of Gene Therapy. 18: 579-87. PMID 19773746 DOI: 10.1038/mt.2009.216  1
2010 Kirik D, Björklund MT, Ramaswamy S, Kordower JH. Novel Gene-Based Therapeutics Targeting the Dopaminergic System in Parkinson's Disease Dopamine Handbook. DOI: 10.1093/acprof:oso/9780195373035.003.0034  1
2009 Björklund A, Björklund T, Kirik D. Gene therapy for dopamine replacement in Parkinson's disease. Science Translational Medicine. 1: 2ps2. PMID 20368161 DOI: 10.1126/scitranslmed.3000350  1
2009 Wilms H, Rosenstiel P, Romero-Ramos M, Arlt A, Schäfer H, Seegert D, Kahle PJ, Odoy S, Claasen JH, Holzknecht C, Brandenburg LO, Deuschl G, Schreiber S, Kirik D, Lucius R. Suppression of MAP kinases inhibits microglial activation and attenuates neuronal cell death induced by alpha-synuclein protofibrils. International Journal of Immunopathology and Pharmacology. 22: 897-909. PMID 20074453  1
2009 Sarkar R, Comment A, Vasos PR, Jannin S, Gruetter R, Bodenhausen G, Hall H, Kirik D, Denisov VP. Proton NMR of (15)N-choline metabolites enhanced by dynamic nuclear polarization. Journal of the American Chemical Society. 131: 16014-5. PMID 19848401 DOI: 10.1021/ja9021304  1
2009 Björklund T, Hall H, Breysse N, Soneson C, Carlsson T, Mandel RJ, Carta M, Kirik D. Optimization of continuous in vivo DOPA production and studies on ectopic DA synthesis using rAAV5 vectors in Parkinsonian rats. Journal of Neurochemistry. 111: 355-67. PMID 19686242 DOI: 10.1111/j.1471-4159.2009.06340.x  1
2009 Thompson LH, Grealish S, Kirik D, Björklund A. Reconstruction of the nigrostriatal dopamine pathway in the adult mouse brain. The European Journal of Neuroscience. 30: 625-38. PMID 19674082 DOI: 10.1111/j.1460-9568.2009.06878.x  1
2009 Ulusoy A, Sahin G, Björklund T, Aebischer P, Kirik D. Dose optimization for long-term rAAV-mediated RNA interference in the nigrostriatal projection neurons. Molecular Therapy : the Journal of the American Society of Gene Therapy. 17: 1574-84. PMID 19584816 DOI: 10.1038/mt.2009.142  1
2009 Petersén A, Hult S, Kirik D. Huntington's disease - new perspectives based on neuroendocrine changes in rodent models. Neuro-Degenerative Diseases. 6: 154-64. PMID 19521064 DOI: 10.1159/000225377  1
2009 Muñoz A, Carlsson T, Tronci E, Kirik D, Björklund A, Carta M. Serotonin neuron-dependent and -independent reduction of dyskinesia by 5-HT1A and 5-HT1B receptor agonists in the rat Parkinson model. Experimental Neurology. 219: 298-307. PMID 19500572 DOI: 10.1016/j.expneurol.2009.05.033  1
2009 Björklund T, Kirik D. Scientific rationale for the development of gene therapy strategies for Parkinson's disease. Biochimica Et Biophysica Acta. 1792: 703-13. PMID 19254760 DOI: 10.1016/j.bbadis.2009.02.009  1
2009 Leriche L, Björklund T, Breysse N, Besret L, Grégoire MC, Carlsson T, Dollé F, Mandel RJ, Déglon N, Hantraye P, Kirik D. Positron emission tomography imaging demonstrates correlation between behavioral recovery and correction of dopamine neurotransmission after gene therapy. The Journal of Neuroscience : the Official Journal of the Society For Neuroscience. 29: 1544-53. PMID 19193901 DOI: 10.1523/JNEUROSCI.4491-08.2009  1
2009 Carlsson T, Carta M, Muñoz A, Mattsson B, Winkler C, Kirik D, Björklund A. Impact of grafted serotonin and dopamine neurons on development of L-DOPA-induced dyskinesias in parkinsonian rats is determined by the extent of dopamine neuron degeneration. Brain : a Journal of Neurology. 132: 319-35. PMID 19039008 DOI: 10.1093/brain/awn305  1
2008 Lundberg C, Björklund T, Carlsson T, Jakobsson J, Hantraye P, Déglon N, Kirik D. Applications of lentiviral vectors for biology and gene therapy of neurological disorders. Current Gene Therapy. 8: 461-73. PMID 19075629 DOI: 10.2174/156652308786847996  1
2008 Muñoz A, Li Q, Gardoni F, Marcello E, Qin C, Carlsson T, Kirik D, Di Luca M, Björklund A, Bezard E, Carta M. Combined 5-HT1A and 5-HT1B receptor agonists for the treatment of L-DOPA-induced dyskinesia. Brain : a Journal of Neurology. 131: 3380-94. PMID 18952677 DOI: 10.1093/brain/awn235  1
2008 Carta M, Carlsson T, Muñoz A, Kirik D, Björklund A. Serotonin-dopamine interaction in the induction and maintenance of L-DOPA-induced dyskinesias. Progress in Brain Research. 172: 465-78. PMID 18772046 DOI: 10.1016/S0079-6123(08)00922-9  1
2008 Wisman LA, Sahin G, Maingay M, Leanza G, Kirik D. Functional convergence of dopaminergic and cholinergic input is critical for hippocampus-dependent working memory. The Journal of Neuroscience : the Official Journal of the Society For Neuroscience. 28: 7797-807. PMID 18667612 DOI: 10.1523/JNEUROSCI.1885-08.2008  1
2008 Thompson LH, Kirik D, Björklund A. Non-dopaminergic neurons in ventral mesencephalic transplants make widespread axonal connections in the host brain. Experimental Neurology. 213: 220-8. PMID 18602916 DOI: 10.1016/j.expneurol.2008.06.005  1
2008 Carta M, Carlsson T, Muñoz A, Kirik D, Björklund A. Involvement of the serotonin system in L-dopa-induced dyskinesias. Parkinsonism & Related Disorders. 14: S154-8. PMID 18579429 DOI: 10.1016/j.parkreldis.2008.04.021  1
2008 Ulusoy A, Kirik D. Can overexpression of parkin provide a novel strategy for neuroprotection in Parkinson's disease? Experimental Neurology. 212: 258-60. PMID 18538324 DOI: 10.1016/j.expneurol.2008.04.026  1
2008 Nygren JM, Liuba K, Breitbach M, Stott S, Thorén L, Roell W, Geisen C, Sasse P, Kirik D, Björklund A, Nerlov C, Fleischmann BK, Jovinge S, Jacobsen SE. Myeloid and lymphoid contribution to non-haematopoietic lineages through irradiation-induced heterotypic cell fusion. Nature Cell Biology. 10: 584-92. PMID 18425115 DOI: 10.1038/ncb1721  1
2008 Irvin DK, Kirik D, Björklund A, Thompson LH. In vivo gene delivery to proliferating cells in the striatum generated in response to a 6-hydroxydopamine lesion of the nigro-striatal dopamine pathway. Neurobiology of Disease. 30: 343-52. PMID 18417351 DOI: 10.1016/j.nbd.2008.02.006  1
2008 Kirik D, Gai WP, Jensen PH. Is alpha-synuclein the culprit of the Parkinsonian neurodegeneration? Experimental Neurology. 209: 3-4. PMID 18179907 DOI: 10.1016/j.expneurol.2007.12.007  1
2008 Ulusoy A, Bjorklund T, Hermening S, Kirik D. In vivo gene delivery for development of mammalian models for Parkinson's disease. Experimental Neurology. 209: 89-100. PMID 18028909 DOI: 10.1016/j.expneurol.2007.09.011  1
2008 Lane EL, Carlsson T, Kirik D, Dunnett SB. Animal models of Parkinson's disease Source Book of Models For Biomedical Research. 313-322. DOI: 10.1007/978-1-59745-285-4_34  1
2008 Björklund T, Morizane A, Kirik D, Brundin P. Future Cell-and Gene-Based Therapies for Parkinson's Disease Therapeutics of Parkinson's Disease and Other Movement Disorders. 145-156. DOI: 10.1002/9780470713990.ch8  1
2007 Enquist IB, Lo Bianco C, Ooka A, Nilsson E, MÃ¥nsson JE, Ehinger M, Richter J, Brady RO, Kirik D, Karlsson S. Murine models of acute neuronopathic Gaucher disease. Proceedings of the National Academy of Sciences of the United States of America. 104: 17483-8. PMID 17954912 DOI: 10.1073/pnas.0708086104  1
2007 Carlsson T, Carta M, Winkler C, Björklund A, Kirik D. Serotonin neuron transplants exacerbate L-DOPA-induced dyskinesias in a rat model of Parkinson's disease. The Journal of Neuroscience : the Official Journal of the Society For Neuroscience. 27: 8011-22. PMID 17652591 DOI: 10.1523/JNEUROSCI.2079-07.2007  1
2007 Breysse N, Carlsson T, Winkler C, Björklund A, Kirik D. The functional impact of the intrastriatal dopamine neuron grafts in parkinsonian rats is reduced with advancing disease. The Journal of Neuroscience : the Official Journal of the Society For Neuroscience. 27: 5849-56. PMID 17537955 DOI: 10.1523/JNEUROSCI.0626-07.2007  1
2007 Kanter-Schlifke I, Georgievska B, Kirik D, Kokaia M. Brain area, age and viral vector-specific glial cell-line-derived neurotrophic factor expression and transport in rat. Neuroreport. 18: 845-50. PMID 17515788 DOI: 10.1097/WNR.0b013e32811e1506  1
2007 Carta M, Carlsson T, Kirik D, Björklund A. Dopamine released from 5-HT terminals is the cause of L-DOPA-induced dyskinesia in parkinsonian rats. Brain : a Journal of Neurology. 130: 1819-33. PMID 17452372 DOI: 10.1093/brain/awm082  1
2007 Carlsson T, Björklund T, Kirik D. Restoration of the striatal dopamine synthesis for Parkinson's disease: viral vector-mediated enzyme replacement strategy. Current Gene Therapy. 7: 109-20. PMID 17430130 DOI: 10.2174/156652307780363125  1
2007 Kanter-Schlifke I, Georgievska B, Kirik D, Kokaia M. Seizure suppression by GDNF gene therapy in animal models of epilepsy. Molecular Therapy : the Journal of the American Society of Gene Therapy. 15: 1106-13. PMID 17387333 DOI: 10.1038/sj.mt.6300148  1
2007 Eslamboli A, Romero-Ramos M, Burger C, Bjorklund T, Muzyczka N, Mandel RJ, Baker H, Ridley RM, Kirik D. Long-term consequences of human alpha-synuclein overexpression in the primate ventral midbrain. Brain : a Journal of Neurology. 130: 799-815. PMID 17303591 DOI: 10.1093/brain/awl382  1
2006 Stott SR, Kirik D. Targeted in utero delivery of a retroviral vector for gene transfer in the rodent brain. The European Journal of Neuroscience. 24: 1897-906. PMID 17067293 DOI: 10.1111/j.1460-9568.2006.05095.x  1
2006 Maingay M, Romero-Ramos M, Carta M, Kirik D. Ventral tegmental area dopamine neurons are resistant to human mutant alpha-synuclein overexpression. Neurobiology of Disease. 23: 522-32. PMID 16806952 DOI: 10.1016/j.nbd.2006.04.007  1
2006 Torres EM, Meldrum A, Kirik D, Dunnett SB. An investigation of the problem of two-layered immunohistochemical staining in paraformaldehyde fixed sections. Journal of Neuroscience Methods. 158: 64-74. PMID 16797719 DOI: 10.1016/j.jneumeth.2006.05.016  1
2006 Winkler C, Georgievska B, Carlsson T, Lacar B, Kirik D. Continuous exposure to glial cell line-derived neurotrophic factor to mature dopaminergic transplants impairs the graft's ability to improve spontaneous motor behavior in parkinsonian rats. Neuroscience. 141: 521-31. PMID 16697115 DOI: 10.1016/j.neuroscience.2006.03.068  1
2006 Carlsson T, Winkler C, Lundblad M, Cenci MA, Björklund A, Kirik D. Graft placement and uneven pattern of reinnervation in the striatum is important for development of graft-induced dyskinesia. Neurobiology of Disease. 21: 657-68. PMID 16256359 DOI: 10.1016/j.nbd.2005.09.008  1
2006 Kirik D, Georgievska B, Behrstock S, Svendsen CN. Delivery of GDNF for Parkinson's disease: Transition of a neuroprotective treatment strategy from basic sciences to clinical application Restorative Therapies in Parkinson's Disease. 297-316. DOI: 10.1007/0-387-32823-2_15  1
2005 Kirik D, Björklund A. Parkinson's disease: viral vector delivery of parkin generates model results in rats. Gene Therapy. 12: 727-9. PMID 19202633 DOI: 10.1002/3527603867.ch2  1
2005 Kirik D, Breysse N, Björklund T, Besret L, Hantraye P. Imaging in cell-based therapy for neurodegenerative diseases. European Journal of Nuclear Medicine and Molecular Imaging. 32: S417-34. PMID 16267643 DOI: 10.1007/s00259-005-1909-6  1
2005 Barraud P, Thompson L, Kirik D, Björklund A, Parmar M. Isolation and characterization of neural precursor cells from the Sox1-GFP reporter mouse. The European Journal of Neuroscience. 22: 1555-69. PMID 16197496 DOI: 10.1111/j.1460-9568.2005.04352.x  1
2005 Thompson L, Barraud P, Andersson E, Kirik D, Björklund A. Identification of dopaminergic neurons of nigral and ventral tegmental area subtypes in grafts of fetal ventral mesencephalon based on cell morphology, protein expression, and efferent projections. The Journal of Neuroscience : the Official Journal of the Society For Neuroscience. 25: 6467-77. PMID 16000637 DOI: 10.1523/JNEUROSCI.1676-05.2005  1
2005 Kirik D, Björklund A. Histological analysis of fetal dopamine cell suspension grafts in two patients with Parkinson's disease gives promising results. Brain : a Journal of Neurology. 128: 1478-9. PMID 15980119 DOI: 10.1093/brain/awh570  1
2005 Sørensen AT, Thompson L, Kirik D, Björklund A, Lindvall O, Kokaia M. Functional properties and synaptic integration of genetically labelled dopaminergic neurons in intrastriatal grafts. The European Journal of Neuroscience. 21: 2793-9. PMID 15926926 DOI: 10.1111/j.1460-9568.2005.04116.x  1
2005 Popovic N, Maingay M, Kirik D, Brundin P. Lentiviral gene delivery of GDNF into the striatum of R6/2 Huntington mice fails to attenuate behavioral and neuropathological changes. Experimental Neurology. 193: 65-74. PMID 15817265 DOI: 10.1016/j.expneurol.2004.12.009  1
2005 Maingay M, Romero-Ramos M, Kirik D. Viral vector mediated overexpression of human alpha-synuclein in the nigrostriatal dopaminergic neurons: a new model for Parkinson's disease. Cns Spectrums. 10: 235-44. PMID 15744224  1
2005 Eslamboli A, Georgievska B, Ridley RM, Baker HF, Muzyczka N, Burger C, Mandel RJ, Annett L, Kirik D. Continuous low-level glial cell line-derived neurotrophic factor delivery using recombinant adeno-associated viral vectors provides neuroprotection and induces behavioral recovery in a primate model of Parkinson's disease. The Journal of Neuroscience : the Official Journal of the Society For Neuroscience. 25: 769-77. PMID 15673656 DOI: 10.1523/JNEUROSCI.4421-04.2005  1
2005 Winkler C, Kirik D, Björklund A. Cell transplantation in Parkinson's disease: how can we make it work? Trends in Neurosciences. 28: 86-92. PMID 15667931 DOI: 10.1016/j.tins.2004.12.006  1
2005 Carlsson T, Winkler C, Burger C, Muzyczka N, Mandel RJ, Cenci A, Björklund A, Kirik D. Reversal of dyskinesias in an animal model of Parkinson's disease by continuous L-DOPA delivery using rAAV vectors. Brain : a Journal of Neurology. 128: 559-69. PMID 15659429 DOI: 10.1093/brain/awh374  1
2004 Georgievska B, Jakobsson J, Persson E, Ericson C, Kirik D, Lundberg C. Regulated delivery of glial cell line-derived neurotrophic factor into rat striatum, using a tetracycline-dependent lentiviral vector. Human Gene Therapy. 15: 934-44. PMID 15585109 DOI: 10.1089/hum.2004.15.934  1
2004 Georgievska B, Carlsson T, Lacar B, Winkler C, Kirik D. Dissociation between short-term increased graft survival and long-term functional improvements in Parkinsonian rats overexpressing glial cell line-derived neurotrophic factor. The European Journal of Neuroscience. 20: 3121-30. PMID 15579166 DOI: 10.1111/j.1460-9568.2004.03770.x  1
2004 Georgievska B, Kirik D, Björklund A. Overexpression of glial cell line-derived neurotrophic factor using a lentiviral vector induces time- and dose-dependent downregulation of tyrosine hydroxylase in the intact nigrostriatal dopamine system. The Journal of Neuroscience : the Official Journal of the Society For Neuroscience. 24: 6437-45. PMID 15269253 DOI: 10.1523/JNEUROSCI.1122-04.2004  1
2004 Kirik D, Georgievska B, Björklund A. Localized striatal delivery of GDNF as a treatment for Parkinson disease. Nature Neuroscience. 7: 105-10. PMID 14747832 DOI: 10.1038/nn1175  1
2003 Arvidsson A, Kirik D, Lundberg C, Mandel RJ, Andsberg G, Kokaia Z, Lindvall O. Elevated GDNF levels following viral vector-mediated gene transfer can increase neuronal death after stroke in rats. Neurobiology of Disease. 14: 542-56. PMID 14678770 DOI: 10.1016/j.nbd.2003.08.002  1
2003 Eslamboli A, Cummings RM, Ridley RM, Baker HF, Muzyczka N, Burger C, Mandel RJ, Kirik D, Annett LE. Recombinant adeno-associated viral vector (rAAV) delivery of GDNF provides protection against 6-OHDA lesion in the common marmoset monkey (Callithrix jacchus). Experimental Neurology. 184: 536-48. PMID 14637123 DOI: 10.1016/j.expneurol.2003.08.007  1
2003 Kirik D, Björklund A. Modeling CNS neurodegeneration by overexpression of disease-causing proteins using viral vectors. Trends in Neurosciences. 26: 386-92. PMID 12850435 DOI: 10.1016/S0166-2236(03)00164-4  1
2003 Gustafsson E, Andsberg G, Darsalia V, Mohapel P, Mandel RJ, Kirik D, Lindvall O, Kokaia Z. Anterograde delivery of brain-derived neurotrophic factor to striatum via nigral transduction of recombinant adeno-associated virus increases neuronal death but promotes neurogenic response following stroke. The European Journal of Neuroscience. 17: 2667-78. PMID 12823474 DOI: 10.1046/j.1460-9568.2003.02713.x  1
2003 Kirik D, Annett LE, Burger C, Muzyczka N, Mandel RJ, Björklund A. Nigrostriatal alpha-synucleinopathy induced by viral vector-mediated overexpression of human alpha-synuclein: a new primate model of Parkinson's disease. Proceedings of the National Academy of Sciences of the United States of America. 100: 2884-9. PMID 12601150 DOI: 10.1073/pnas.0536383100  1
2003 Rosenblad C, Georgievska B, Kirik D. Long-term striatal overexpression of GDNF selectively downregulates tyrosine hydroxylase in the intact nigrostriatal dopamine system. The European Journal of Neuroscience. 17: 260-70. PMID 12542662 DOI: 10.1046/j.1460-9568.2003.02456.x  1
2002 Georgievska B, Kirik D, Björklund A. Aberrant sprouting and downregulation of tyrosine hydroxylase in lesioned nigrostriatal dopamine neurons induced by long-lasting overexpression of glial cell line derived neurotrophic factor in the striatum by lentiviral gene transfer. Experimental Neurology. 177: 461-74. PMID 12429192 DOI: 10.1006/exnr.2002.8006  1
2002 Arvidsson A, Collin T, Kirik D, Kokaia Z, Lindvall O. Neuronal replacement from endogenous precursors in the adult brain after stroke. Nature Medicine. 8: 963-70. PMID 12161747 DOI: 10.1038/nm747  1
2002 Winkler C, Kirik D, Björklund A, Cenci MA. L-DOPA-induced dyskinesia in the intrastriatal 6-hydroxydopamine model of parkinson's disease: relation to motor and cellular parameters of nigrostriatal function. Neurobiology of Disease. 10: 165-86. PMID 12127155 DOI: 10.1006/nbdi.2002.0499  1
2002 Georgievska B, Kirik D, Rosenblad C, Lundberg C, Björklund A. Neuroprotection in the rat Parkinson model by intrastriatal GDNF gene transfer using a lentiviral vector. Neuroreport. 13: 75-82. PMID 11924898  1
2002 Kirik D, Rosenblad C, Burger C, Lundberg C, Johansen TE, Muzyczka N, Mandel RJ, Björklund A. Parkinson-like neurodegeneration induced by targeted overexpression of alpha-synuclein in the nigrostriatal system. The Journal of Neuroscience : the Official Journal of the Society For Neuroscience. 22: 2780-91. PMID 11923443  1
2002 Kirik D, Georgievska B, Burger C, Winkler C, Muzyczka N, Mandel RJ, Bjorklund A. Reversal of motor impairments in parkinsonian rats by continuous intrastriatal delivery of L-dopa using rAAV-mediated gene transfer. Proceedings of the National Academy of Sciences of the United States of America. 99: 4708-13. PMID 11917105 DOI: 10.1073/pnas.062047599  1
2002 Lundblad M, Andersson M, Winkler C, Kirik D, Wierup N, Cenci MA. Pharmacological validation of behavioural measures of akinesia and dyskinesia in a rat model of Parkinson's disease. The European Journal of Neuroscience. 15: 120-32. PMID 11860512 DOI: 10.1046/j.0953-816x.2001.01843.x  1
2001 Kirik D, Georgievska B, Rosenblad C, Björklund A. Delayed infusion of GDNF promotes recovery of motor function in the partial lesion model of Parkinson's disease. The European Journal of Neuroscience. 13: 1589-99. PMID 11328352  0.92
2001 Kirik D, Winkler C, Björklund A. Growth and functional efficacy of intrastriatal nigral transplants depend on the extent of nigrostriatal degeneration. The Journal of Neuroscience : the Official Journal of the Society For Neuroscience. 21: 2889-96. PMID 11306640  1
2000 Winkler C, Kirik D, Björklund A, Dunnett SB. Transplantation in the rat model of Parkinson's disease: ectopic versus homotopic graft placement. Progress in Brain Research. 127: 233-65. PMID 11142030 DOI: 10.1016/S0079-6123(00)27012-X  1
2000 Björklund A, Kirik D, Rosenblad C, Georgievska B, Lundberg C, Mandel RJ. Towards a neuroprotective gene therapy for Parkinson's disease: use of adenovirus, AAV and lentivirus vectors for gene transfer of GDNF to the nigrostriatal system in the rat Parkinson model. Brain Research. 886: 82-98. PMID 11119690 DOI: 10.1016/S0006-8993(00)02915-2  1
2000 Kirik D, Rosenblad C, Björklund A. Preservation of a functional nigrostriatal dopamine pathway by GDNF in the intrastriatal 6-OHDA lesion model depends on the site of administration of the trophic factor. The European Journal of Neuroscience. 12: 3871-82. PMID 11069582  0.76
2000 Fricker-Gates RA, Winkler C, Kirik D, Rosenblad C, Carpenter MK, Björklund A. EGF infusion stimulates the proliferation and migration of embryonic progenitor cells transplanted in the adult rat striatum. Experimental Neurology. 165: 237-47. PMID 10993684 DOI: 10.1006/exnr.2000.7482  1
2000 Kirik D, Rosenblad C, Bjorklund A, Mandel RJ. Long-term rAAV-mediated gene transfer of GDNF in the rat Parkinson's model: intrastriatal but not intranigral transduction promotes functional regeneration in the lesioned nigrostriatal system. The Journal of Neuroscience : the Official Journal of the Society For Neuroscience. 20: 4686-700. PMID 10844038  1
2000 Keynes R, Kirik D, Nieto-Sampedro M. European neuroscience meets the snow. Trends in Neurosciences. 23: 91-2. PMID 10722395 DOI: 10.1016/S0166-2236(00)01551-4  1
2000 Rosenblad C, Kirik D, Björklund A. Sequential administration of GDNF into the substantia nigra and striatum promotes dopamine neuron survival and axonal sprouting but not striatal reinnervation or functional recovery in the partial 6-OHDA lesion model. Experimental Neurology. 161: 503-16. PMID 10686072 DOI: 10.1006/exnr.1999.7296  0.76
2000 Rosenblad C, Grønborg M, Hansen C, Blom N, Meyer M, Johansen J, Dagø L, Kirik D, Patel UA, Lundberg C, Trono D, Björklund A, Johansen TE. In vivo protection of nigral dopamine neurons by lentiviral gene transfer of the novel GDNF-family member neublastin/artemin. Molecular and Cellular Neurosciences. 15: 199-214. PMID 10673327 DOI: 10.1006/mcne.1999.0817  1
1999 Rosenblad C, Kirik D, Björklund A. Neurturin enhances the survival of intrastriatal fetal dopaminergic transplants. Neuroreport. 10: 1783-7. PMID 10501575  0.76
1999 Rosenblad C, Kirik D, Devaux B, Moffat B, Phillips HS, Björklund A. Protection and regeneration of nigral dopaminergic neurons by neurturin or GDNF in a partial lesion model of Parkinson's disease after administration into the striatum or the lateral ventricle. The European Journal of Neuroscience. 11: 1554-66. PMID 10215908  0.76
1998 Kirik D, Rosenblad C, Björklund A. Characterization of behavioral and neurodegenerative changes following partial lesions of the nigrostriatal dopamine system induced by intrastriatal 6-hydroxydopamine in the rat. Experimental Neurology. 152: 259-77. PMID 9710526 DOI: 10.1006/exnr.1998.6848  0.76
1998 Horger BA, Nishimura MC, Armanini MP, Wang LC, Poulsen KT, Rosenblad C, Kirik D, Moffat B, Simmons L, Johnson E, Milbrandt J, Rosenthal A, Bjorklund A, Vandlen RA, Hynes MA, et al. Neurturin exerts potent actions on survival and function of midbrain dopaminergic neurons. The Journal of Neuroscience : the Official Journal of the Society For Neuroscience. 18: 4929-37. PMID 9634558  1
1997 Björklund A, Rosenblad C, Winkler C, Kirik D. Studies on neuroprotective and regenerative effects of GDNF in a partial lesion model of Parkinson's disease. Neurobiology of Disease. 4: 186-200. PMID 9361295 DOI: 10.1006/nbdi.1997.0151  1
Show low-probability matches.